Faster global financial news!
Exelixis (EXEL) stock fell early Thursday after the biotechnology company reported mixed second-quarter earnings, with sales of its core cancer drug cabozantinib missing expectations.
svmuu.com06/08/2026 13:00
Complaint Report
Complaint Report
The company's cancer drug Cabometyx had quarterly sales of $570.6 million.
Source：Yahoo财经 · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
Polkadot (DOT) Partner Network: A Key Driver for the Development of the Multichain Ecosystem
-
2
Can FIL Coin Rival Bitcoin? An In-depth Analysis of Filecoin's Potential and Challenges
-
3
What is SILV2 Coin? Analyzing its Role in the Illuvium Ecosystem and Current Trading Status
-
4
QUOTH Coin Value Analysis: An In-depth Look at its Market Status and Investment Risks
-
5
YEON Token: Current Status and High-Risk Analysis of a Decentralized Metaverse Project
-
6
How to Trade WINkLink (WIN) Tokens? Understanding Its Buying and Selling Channels
-
7
TULIP Protocol (TULIP) Token Trading Guide and Listing Platforms
-
8
What is DOGECOLA coin? Understanding its current status and trading channels
-
9
USDT and Bitcoin Trading Platforms: How to Choose and Main Trading Channels
-
10
What is NPXS Coin? The Current Status and Trading Guide for Pundi X's Old Token
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
